Glioblastoma multiforme (GBM) grade IV (WHO) represent 50–60% of diagnosed adult primary CNS tumours. Patients have unfavorable prognosis, with a median survival of about 12 months. GBM is a highly invasive, amenable to a complete resection what is the main cause of recurrence or disease progression. The treatment is quite limited and only few molecular or genetic predictive / prognostic markers were described. The aim of this study is to verify the importance of the selected molecular and genetic markers for the disease prediction or as the possible therapeutic targets. Formalin-fixed, paraffin-embedded (FFPE) samples from 149 glioma patients treated in the University Hospital Olomouc, Czech Republic, have been collected prospectively and systematically since 2006. All patients were discussed in a comprehensive oncology team and underwent early post-surgical MRI (up to 72 hours) to determine resection radicality. Whenever possible, patients were recommended to the Stupp therapy protocol. FISH analysis was performed on FFPE tissues for detection of genes and chromosomal region status (1p, 9p, 19q, EGFR, MDM2, PTEN, TP53, CCND1, C-MYC and RB1, including enumeration of chromosomes on which the genes are localized (chromosome 7, 10, 11, 12, 13, 17 and 22). Using real-time methylation specific PCR, MGMT methylation status was also described. Association of clinical parameters and molecular markers were analyzed by Pearson chi-square test and Fisher test, to analyze differences in survival groups was used log-rank test. It was analyzed overall survival (OS) and graphically depicted by the Kaplan-Meier curves. Effect of different markers was analyzed by the Cox model, even with adjustment, the main clinical factors, e.g. age at diagnosis, performance status or type of treatment. We found statistically significant correlation. For example, MGMT methylation status and the copy numbers of the CCND1, TP53 and RB1 genes seems to be important for predicting response in patients undergoing radiotherapy or chemo-radiotherapy. On other hand, high amplification of EGFR gene (despite is often found in GBM) does not seem to have any prognostic or predictive impact, although increased copy of chromosome 7, where EGFR is localized, seems to be marker of lower hazard ratio. Some other genes are contemporary analyzed and the complete results will be presented. Despite intensive research, radiotherapy and Temodal remains practically as the only treatment for GBM gr.IV. Our study is trying to find other markers for better prediction of tumor prognosis or for biological treatment of the individual patient. The project was supported by Support of Sustainability of the Institute of Molecular and Translational Medicine NPU LO1304; Center of Competence for Molecular Diagnostics and Personalized Medicine TE02000058 and IGA MZČR NT13581 project.